NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free AKRO Stock Alerts $20.79 +0.03 (+0.14%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$19.89▼$20.9650-Day Range$20.51▼$31.1852-Week Range$11.25▼$58.38Volume711,336 shsAverage Volume713,442 shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$37.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Akero Therapeutics alerts: Email Address Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside81.4% Upside$37.71 Price TargetShort InterestHealthy11.34% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.34Based on 5 Articles This WeekInsider TradingSelling Shares$3.32 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.06) to ($4.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.58 out of 5 starsMedical Sector270th out of 910 stocksPharmaceutical Preparations Industry112th out of 422 stocks 3.4 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.34% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Akero Therapeutics has recently decreased by 17.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 1.9 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Akero Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,319,877.00 in company stock.Percentage Held by InsidersOnly 9.69% of the stock of Akero Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($4.06) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -7.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -7.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesApril 4, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 5,000 SharesApril 23, 2024 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Receives New Coverage from Analysts at Bank of AmericaApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROApril 20, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of "Buy" from AnalystsApril 7, 2024 | stockhouse.comAkero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROApril 3, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 3, 2024 | seekingalpha.comAkero Therapeutics' EFX Data Warrants CautionApril 2, 2024 | prnewswire.comAdemi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.March 28, 2024 | msn.com4D Molecular slips after regulatory update on lead assetMarch 18, 2024 | finance.yahoo.comOzempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of ThatMarch 17, 2024 | investing.comAkero Therapeutics CSO sells shares worth over $17kMarch 17, 2024 | investing.comAkero Therapeutics CFO sells shares to cover tax withholdingMarch 16, 2024 | finance.yahoo.comAKRO Apr 2024 42.500 callMarch 16, 2024 | msn.comMadrigal’s stock surges as FDA approves first drug for liver disease MASHMarch 15, 2024 | msn.comMadrigal climbs amid hopes for new NASH drug; B. Riley upgradesMarch 10, 2024 | finance.yahoo.comAKRO Aug 2024 30.000 putMarch 9, 2024 | finance.yahoo.comAKRO Aug 2024 17.500 putMarch 8, 2024 | globenewswire.comAkero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesMarch 8, 2024 | markets.businessinsider.comAkero Therapeutics’ Strong Trial Results and Market Positioning Justify Buy RatingMarch 8, 2024 | finance.yahoo.comAKRO Jan 2025 2.500 callMarch 7, 2024 | globenewswire.comAkero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and HepatologyMarch 7, 2024 | finance.yahoo.comPresident and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)March 6, 2024 | msn.comAkero's fatty liver disease drug lessens scarring in mid-stage trialMarch 6, 2024 | msn.comAkero Therapeutics announces pricing of stock offering to raise $319MSee More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/22/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$37.71 High Stock Price Target$43.00 Low Stock Price Target$30.00 Potential Upside/Downside+81.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.59% Return on Assets-27.10% Debt Debt-to-Equity Ratio0.05 Current Ratio29.27 Quick Ratio29.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.61 per share Price / Book2.16Miscellaneous Outstanding Shares69,150,000Free Float62,450,000Market Cap$1.44 billion OptionableOptionable Beta-0.38 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.22MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $763.3kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Comp: $819.4kMr. William R. White J.D. (Age 50)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $768.4kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Comp: $754.8kMr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy Mr. John J. Schembri (Age 62)VP of Finance & Controller More ExecutivesKey CompetitorsAlbireo PharmaNASDAQ:ALBOIcosavaxNASDAQ:ICVXGracell BiotechnologiesNASDAQ:GRCLDianthus TherapeuticsNASDAQ:DNTHWave Life SciencesNASDAQ:WVEView All CompetitorsInsiders & InstitutionsBourgeon Capital Management LLCBought 15,150 shares on 4/19/2024Ownership: 0.022%Quattro Financial Advisors LLCBought 9,977 shares on 4/18/2024Ownership: 0.018%Los Angeles Capital Management LLCBought 8,343 shares on 4/5/2024Ownership: 0.015%Jonathan YoungSold 5,000 sharesTotal: $121,900.00 ($24.38/share)Kingdon Capital Management L.L.C.Sold 79,500 shares on 3/18/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price target for 2024? 7 analysts have issued twelve-month price objectives for Akero Therapeutics' shares. Their AKRO share price targets range from $30.00 to $43.00. On average, they predict the company's share price to reach $37.71 in the next year. This suggests a possible upside of 81.4% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2024? Akero Therapeutics' stock was trading at $23.35 at the beginning of the year. Since then, AKRO stock has decreased by 11.0% and is now trading at $20.79. View the best growth stocks for 2024 here. Are investors shorting Akero Therapeutics? Akero Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 7,840,000 shares, a drop of 17.2% from the March 15th total of 9,470,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 5.8 days. View Akero Therapeutics' Short Interest. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.17. What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Health Care ETF (PINK). What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.02%), Quattro Financial Advisors LLC (0.02%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKRO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
